Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
prolong ejaculation.
Popular Articles

Treating Gum Disease Helps Rheumatoid Arthritis Sufferers
Not yet convinced about keeping your healthy teeth, here"s another reason.
generic viagra
Mabthera(R) (Rituximab) Available On NHS For UK's Most Common Leukaemia
The National Institute for Health and Clinical Excellence (NICE) today issued its recommendation for the use of MabThera® (rituximab) in the UK"s most common form of leukaemia, chronic lymphocytic leukaemia (CLL).1,2,3 NICE"s final guidance recommends rituximab in combination with fludarabine and cyclophosphamide (FC) chemotherapy as an option for previously untreated patients with CLL.4 The addition of rituximab to FC chemotherapy has been proven to halt progression of the disease by 10.5 months longer than chemotherapy alone, and more than doubles the number of CLL patients achieving complete remission, compared to chemotherapy.5,6 More than 20,000 people in the UK are living with CLL and there are an estimated 3,700 new cases every year.7,8 Professor John Gribben, Consultant Haematologist and Medical Oncologist, Barts and The London NHS Trust, commented:
News of the day
What Are Gallstones? What Causes Gallstones?
Gallstones are lumps or stones that develop in the gallbladder or bile duct. Some of the chemicals which exist in the gallbladder, such as cholesterol, calcium bilirubinate, and calcium carbonate, harden into either one large stone or many small ones. According to Medilexicon"s medical dictionary, a gallstone is "A concretion in the gallbladder or a bile duct, composed chiefly of a mixture of cholesterol, calcium bilirubinate, and calcium carbonate, occasionally as a pure stone composed of just one of these substances". An article describes a gallbladder in the bile duct similar to trying to squeeze a golf ball through a straw.
Mental Health

MMR Information Systems Pursues International Patent Applications On Anti-CD20 Antibodies

MMR Information Systems, Inc. (OTCBB: MMRF) (the "Company"), which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") provides consumer-controlled Personal Health Records ("PHRs") (http://www.mymedicalrecords.com) and electronic safe deposit box storage solutions (http://www.myesafedepositbox.com), announced that it has taken the necessary steps to file for extensions of the Company"s Patent Cooperation Treaty (PCT) patent application on anti-CD20 monoclonal antibodies to the national phase through filings in major European, Asian, North American, and South American markets. Anti-CD20 antibodies are useful in treating B-Cell malignancies, including Non-Hodgkin Lymphoma (NHL) and additional B-Cell mediated conditions such as rheumatoid arthritis. The Company"s anti-CD20 antibody asset is potentially a candidate for the next generation Rituximab. Rituximab, currently marketed under the trade name Rituxan® in the United States by Biogen Idec and Genentech (wholly owned member of the Roche Group) and under the name MabThera® by Roche in the rest of the world except Japan, where it is co-marketed by Chugai and Zenyaku Kogyo Co. Ltd., is one of the world"s most successful monoclonal antibodies with reported total sales in 2008 in excess of USD $5.4 billion. MMR Information Systems, Inc. acquired the technology through its reverse merger with Favrille, Inc., which was completed in January 2009. Favrille had previously acquired the technology from Diversa Corporation (now Verenium Corporation). According to consultants to the Company and former science executives of Favrille, Inc., and based on Diversa"s pre-clinical research and testing of the scientific evidence, the next generation of Rituximab and further applications of the anti-CD20 antibodies may make the treatment of B-Cell malignancies even more effective in the future. This second generation technology includes a series of optimized anti-CD20 monoclonal antibodies and provides potential future treatment options for various autoimmune and B-Cell mediated diseases, including lupus nephritis, systemic lupus erythematosus, psoriasis, inflammatory bowel disease, respiratory distress syndrome, chronic lymphocytic leukemia, multiple sclerosis and vaculitis. Because of its interest in maximizing shareholder value, MMR Information Systems is working with independent consultants to attempt to monetize these anti-CD20 antibody assets around the world, and will attend meetings at the Drug Information Association"s (DIA) Annual Meeting being held in San Diego this week. However, the Company"s focus will continue to be on its primary products, the MyMedicalRecords Personal Health Record, MyMedicalRecords Pro for physicians and healthcare professionals, and MyEsafeDepositBox electronic safe deposit box storage solutions. MMR Information Systems, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009